兰卫医学：2024 年度内部控制评价报告 上海兰卫医学检验所股份有限公司 2024 年度内部控制评价报告 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称"企业内部控制规范体系"），结合上海兰卫医学检验所股份有限公 司（以下简称"公司"）相关规章制度，在内部控制日常监督和专项监督的基础 上，我们对公司截至 2024 年 12 月 31 日（内部控制评价报告基准日）的内部控 制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-017 上海兰卫医学检验所股份有限公司 关于召开 2024 年年度股东大会的通知公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开 了第四届董事会第三次会议，审议通过了《关于提请召开公司 2024 年年度股东大会的 议案》，决定于 2025 年 5 月 23 日（星期五）召开公司 2024 年年度股东大会。现将会议 相关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：公司董事会 3、会议召开的合法、合规性：经公司第四届董事会第三次会议审议通过，决定召 开公司 2024 年年度股东大会。本次股东大会的召集、召开符合有关法律、行政法规、 部门规章、规范性文件、深圳证券交易所业务规则和《上海兰卫医学检验所股份有限公 司章程》等规定。 4、会议召开的日期、时间： 现场会议召开时间：2025 年 5 月 23 日（星期五）下午 14:30。 网络投票时间：20 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-007 上海兰卫医学检验所股份有限公司 第四届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届监事会第三次会议 于 2025 年 4 月 24 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通知 已于 2025 年 4 月 11 日以邮件形式通知全体监事。会议由公司监事会主席朱剑先生召集 和主持，本次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开和表决 程序符合《中华人民共和国公司法》《上海兰卫医学检验所股份有限公司章程》（以下简 称"《公司章程》"）规定，会议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于公司 2024 年年度报告及其摘要的议案》 经审核，监事会认为董事会编制和审核公司 2024 年年度报告的程序符合法律、行 政法规、中国证监会、深圳证券交易所的各项规定；报告内容真实 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-006 上海兰卫医学检验所股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第三次会议 于 2025 年 4 月 24 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通知 已于 2025 年 4 月 11 日以邮件形式通知全体董事。会议由公司董事长曾伟雄先生主持， 本次会议应出席董事 7 人，实际出席董事 7 人。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》（以下简称"《公司法》"）《上海兰卫医学检验所股份有限公 司章程》（以下简称"《公司章程》"）规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于公司 2024 年年度报告及其摘要的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年年度 报告》（公告编号：20 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-008 上海兰卫医学检验所股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、上海兰卫医学检验所股份有限公司（以下简称"公司"）拟定的 2024 年度利润 分配预案为：拟以 2024 年 12 月 31 日公司总股本 400,517,000 股剔除公司回购专用账户 股份数量后的总股本 398,520,900 股为基数，向全体股东每 10 股派发现金股利人民币 2.00 元（含税），共计派发现金股利人民币 79,704,180.00 元（含税），不送红股，不以资 本公积金转增股本，剩余未分配利润结转以后年度分配。 2、公司现金分红方案不触及《深圳证券交易所创业板股票上市规则》第 9.4 条相 关规定的可能被实施其他风险警示情形。 一、审议程序 （一）董事会意见 公司第四届董事会第三次会议审议通过了《关于公司 2024 年度利润分配方案的议 案》，公司董事会认为该利润分配预案在保证公司正常经营和长远发展的前提下，能更 好地兼顾股东尤其是 ...

Financial Performance - The company reported a net loss primarily due to credit impairment losses and asset impairment losses during the reporting period[4]. - The company's operating revenue for 2024 was ¥1,742,181,004.45, representing a 4.05% increase compared to ¥1,674,368,547.18 in 2023[18]. - The net profit attributable to shareholders for 2024 was -¥109,436,220.80, an improvement of 22.71% from -¥141,591,451.29 in 2023[18]. - The net cash flow from operating activities decreased by 60.45% to ¥216,312,816.18 in 2024, down from ¥546,988,461.38 in 2023[18]. - The total assets at the end of 2024 were ¥2,623,334,426.70, a decrease of 12.17% from ¥2,986,860,553.79 at the end of 2023[18]. - The net assets attributable to shareholders decreased by 6.86% to ¥1,658,128,422.29 at the end of 2024, compared to ¥1,780,316,277.50 at the end of 2023[18]. - The basic earnings per share for 2024 was -¥0.27, an improvement of 22.86% from -¥0.35 in 2023[18]. - The company reported a total of ¥14,349,920.59 in government subsidies for 2024, down from ¥31,798,793.60 in 2023[24]. Operational Stability - The company has not experienced any changes in its registered address during the reporting period, maintaining operational stability[14]. - The company’s registered office and operational address remain consistent, located in Shanghai, which supports its operational efficiency[14]. - The financial report is guaranteed to be true, accurate, and complete by the company's management, ensuring accountability[4]. - The company emphasizes that forward-looking statements regarding future plans and development strategies do not constitute substantive commitments to investors, highlighting the need for risk awareness[4]. Risk Management - The company is committed to addressing potential operational risks and has outlined corresponding measures in the management discussion section of the report[4]. - The company has engaged Rongcheng Accounting Firm for auditing services, ensuring compliance and accuracy in financial reporting[17]. Market Trends and Opportunities - The medical service industry is expected to continue expanding due to increasing healthcare demands driven by an aging population and greater health awareness[28]. - The company is positioned to benefit from ongoing medical reforms and increasing demand for drug innovation within the clinical testing market[29]. - The clinical testing industry in China grew from RMB 352.8 billion in 2017 to RMB 542.4 billion in 2021, with a CAGR of 11.4%, and is expected to reach RMB 896.4 billion by 2026, with a CAGR of 10.6%[31]. - The government is accelerating the construction of national medical centers and regional medical centers to enhance the medical capabilities of city and county-level hospitals, which will create new business expansion opportunities for ICL suppliers[36]. Strategic Initiatives - The company is expanding its medical diagnostic services, establishing a network of specialized laboratories to enhance quality management and technical service projects[47]. - The company has formed strategic partnerships with leading IVD manufacturers, focusing on research and clinical trials, particularly in oncology and genetic diseases[48]. - The company is developing a multi-omics platform and has established an innovation center, collaborating with Roche Diagnostics and 10x Genomics to enhance research capabilities[49]. - The company is actively involved in academic exchanges and collaborations with top hospitals, supporting specialized alliances to empower regional healthcare institutions[50]. Financial Management - The company has reported a significant decrease in total investments, with an investment amount of 308,615,801.84, down 52.55% from the previous year's 650,408,651.63[103]. - The company’s goodwill decreased to 7,664,887.29, accounting for 0.29% of total assets, primarily due to the disposal of subsidiaries[98]. - The company’s long-term equity investments were valued at 1,759,448.90, down from 14,064,185.61, a decrease of 0.40% in proportion to total assets[96]. Governance and Compliance - The board of directors has been restructured, now comprising 7 members, including 3 independent directors, ensuring compliance with governance standards[135]. - The company has established a robust internal management and control system to ensure effective governance and protect investor interests[132]. - The company has established a dedicated internal audit department to ensure the authenticity and completeness of financial information and internal control systems[137]. - The company strictly adheres to legal regulations for information disclosure, ensuring timely and fair access to information for all investors[139]. Shareholder Relations - The company emphasizes investor relations management, with a participation rate of 61.53% in the 2023 annual general meeting[149]. - The company plans to distribute a cash dividend of CNY 2.00 per 10 shares, totaling CNY 79,704,180.00, based on a total share capital of 398,520,900 shares[179]. - The cash dividend represents 100% of the total profit distribution amount, with no stock dividends or capital reserve transfers planned[178]. Research and Development - The company is investing in R&D, allocating $F million towards new technologies aimed at enhancing operational efficiency and product offerings[160]. - The company is developing a high-sensitivity digital PCR kit for chronic myeloid leukemia detection, aiming for a detection sensitivity of 10^-6[89]. - The company is also working on a tuberculosis detection kit using oral swabs, targeting high-burden countries like China and India[89]. Employee Management - The total number of employees at the end of the reporting period is 1,365, with 246 in the parent company and 606 in major subsidiaries[172]. - The professional composition includes 735 technical personnel, 154 sales personnel, 54 financial personnel, and 422 administrative personnel[172]. - The company has established a comprehensive compensation system that includes fixed salaries and variable components such as performance bonuses and stock incentives[173]. Environmental Responsibility - The company promotes a low-carbon and environmentally friendly philosophy, integrating it into all aspects of its operations[186]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[186]. Future Commitments - The company commits to not transferring or entrusting shares for 36 months post-IPO, ensuring shareholder stability[190]. - The company will ensure compliance with the relevant laws and regulations regarding shareholding and reduction commitments[191]. - The company has established a plan to stabilize its stock price for three years post-listing, which includes specific obligations and responsibilities[191].

Financial Performance - The company's revenue for Q1 2025 was ¥350,884,969.11, a decrease of 19.60% compared to ¥436,441,198.76 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥8,080,860.79, representing a decline of 854.01% from a profit of ¥1,071,720.66 in the previous year[5] - The company's operating profit turned negative at ¥-6,673,526.50, down from a profit of ¥2,720,970.17 in the previous period[17] - Net profit for the period was a loss of ¥8,426,252.98 compared to a loss of ¥264,826.54 in the previous period, indicating a significant decline in profitability[18] - Basic and diluted earnings per share were both ¥-0.0203, compared to ¥0.0027 in the previous period, reflecting a substantial decrease[18] Cash Flow - The net cash flow from operating activities improved to ¥1,658,133.01, a significant increase of 104.28% compared to a negative cash flow of ¥38,737,542.37 in Q1 2024[5] - Net cash flow from operating activities was 1,658,133.01, a significant improvement from a negative cash flow of -38,737,542.37 in the previous period[21] - Cash received from sales of goods and services was ¥401,580,869.23, down from ¥420,445,869.80, a decrease of approximately 4.1% year-over-year[20] - Cash inflow from investment activities totaled 256,036,805.39, compared to 50,195,671.23 in the prior period, indicating a strong increase in investment recovery[21] - Cash outflow from investment activities was 321,572,288.15, up from 67,653,847.10, leading to a net cash flow from investment activities of -65,535,482.76, worsening from -17,458,175.87[21] - Total cash flow from financing activities resulted in a net outflow of -19,708,529.29, compared to -14,143,681.47 in the previous period[22] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥2,616,249,615.91, a slight decrease of 0.27% from ¥2,623,334,426.70 at the end of the previous year[5] - Total current assets amount to CNY 2,007,317,551.25, slightly up from CNY 1,998,640,598.09 at the beginning of the period[15] - Total liabilities increased slightly to ¥804,339,369.72 from ¥802,997,927.54, indicating a stable financial position[16] - Non-current liabilities decreased to ¥174,021,754.03 from ¥187,408,532.33, a reduction of about 7.1% year-over-year[16] - The total equity attributable to shareholders decreased to ¥1,650,047,561.50 from ¥1,658,128,422.29, a decline of approximately 0.5%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 24,149[12] - The largest shareholder, Shanghai Lanwei Investment Co., holds 37.34% of shares, totaling 149,554,017 shares[12] Operational Efficiency - The company reported a significant increase in prepayments by 119.12%, rising to ¥10,423,796.74 from ¥4,757,068.96[10] - Financial expenses surged by 226.25% to ¥747,936.18, primarily due to a reduction in supplier discount income[10] - The company recorded a decrease in income tax expenses by 48.18%, amounting to ¥1,338,717.60, due to reduced profits[10] - Cash paid for employee compensation was 70,124,452.22, slightly up from 69,042,247.42, showing stable labor costs[21] - The company’s cash flow from operating activities was impacted by a total outflow of 404,955,588.09, down from 464,780,873.64, indicating improved operational efficiency despite higher outflows[21]

最新一期业绩显示，2024年三季报，公司实现营业收入13.20亿元，同比3.95%；净利润-40583766.31 元，同比-4511.40%，销售毛利率21.00%。 上海兰卫医学检验所股份有限公司是一家为检验诊断行业提供整体解决方案的综合服务商，面向各级医 疗机构提供第三方医学检验和病理诊断服务、国内外知名品牌体外诊断产品以及其他专业技术支持，以 满足各级医疗机构差异化需求。公司主要服务和产品有医学检验及病理诊断服务、体外诊断产品等。公 司通过多年来代理销售罗氏、希森美康、徕卡和DAKO等世界一流的医学检验和病理诊断产品，形成了 覆盖全国多个省份的销售网络，特别是在湖南湖北地区具有较高的市场占有率、市场知名度和美誉度， 成长为一家能够提供技术推广、物流配送、售后维护和技术支持的综合服务商。 4月8日，兰卫医学今日收盘8.36元，上涨4.24%，最新市净率1.93，总市值33.48亿元。 截至2024年三季报，共有38家机构持仓兰卫医学，其中基金38家，合计持股数82.12万股，持股市值0.07 亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)17兰卫医学-18.47-23.651.9333. ...

Group 1 - The core viewpoint of the article highlights the financial performance and market position of Lanwei Medical, indicating a decline in stock price and net profit for the recent quarter [1] - As of September 30, 2024, the number of shareholders for Lanwei Medical increased to 28,060, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - Lanwei Medical provides comprehensive solutions for the diagnostic industry, offering third-party medical testing and pathology diagnosis services, as well as in vitro diagnostic products [1] Group 2 - The latest financial report for the third quarter of 2024 shows that the company achieved a revenue of 1.32 billion yuan, representing a year-on-year increase of 3.95%, while the net profit was a loss of approximately 40.58 million yuan, a significant decline of 4,511.40% year-on-year [1] - The gross profit margin for the company stands at 21.00% [1] - The company has established a strong sales network across multiple provinces in China, particularly in Hunan and Hubei, enhancing its market share and brand recognition [1]

财联社1月9日电，兰卫医学直线拉升20CM涨停，达安基因涨停，之江生物、海辰药业涨超5%，凯普生 物、西点药业、亚太药业等跟涨。 消息面上，据中国疾控中心官网，近日，我国发现一起猴痘病毒Ib亚分支聚集性疫情，传染源为1位外 籍人员，有刚果（金）旅居史。 ...